Latest Period
Q1 2026
Security Snapshot
Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership
CUSIP: 046513206
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
33
Shares (Excl. Options)
2,564,231
Price
$4.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ATRA on Nasdaq
- Shares outstanding
- 8,191,888
- Reported price per share
- $10.48
- Price from insider filings
- $10.48
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,564,231
- Total reported value
- $12,126,243
- Portfolio coverage rank
- 0%
- Share change
- +487,541
- Value change
- -$2,698,909
- Number of holders
- 33
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ATRA - Atara Biotherapeutics, Inc. - Common Stock is tracked under CUSIP 046513206.
- 33 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 40 to 33 between Q4 2025 and Q1 2026.
- Reported value moved from $37,062,796 to $12,126,243.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 33 institutions filings for Q1 2026.
Security key
046513206
Latest holder period
Q1 2026
13F holders
33
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
ATRA full holder history
Atara Biotherapeutics, Inc. SEC filings
Atara Biotherapeutics, Inc. company facts
Atara Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 046513206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
ATRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | 16% | +66% | $6,449,392 | +$3,759,892 | 1,318,894 | +140% | Panacea Innovation Limited | 07 May 2026 |
| Redmile Group, LLC | 9.9% | 0% | $10,764,875 | +$659,400 | 751,223 | +6.5% | Redmile Group, LLC | 12 Nov 2025 |
| EcoR1 Capital, LLC | 9.9% | $10,258,030 | 715,853 | EcoR1 Capital, LLC | 30 Sep 2025 |
As of 31 Mar 2026, 33 institutional investors reported holding 2,564,231 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 31% of the company’s total 8,191,888 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
31%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.5% | 700,000 | 0.01% | $3,311,000 | |
| Redmile Group, LLC | 5.4% | 441,701 | 0% | 0.14% | $2,089,246 |
| MACKENZIE FINANCIAL CORP | 3.8% | 313,620 | +435% | 0% | $1,483,423 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 217,862 | 0% | 0% | $1,030,487 |
| Point72 Asset Management, L.P. | 2.4% | 194,264 | +962% | 0% | $918,869 |
| ACADIAN ASSET MANAGEMENT LLC | 1.6% | 130,910 | +142% | 0% | $617,000 |
| EcoR1 Capital, LLC | 1.2% | 99,593 | -83% | 0.02% | $471,075 |
| BlackRock, Inc. | 0.96% | 79,022 | +18% | 0% | $373,773 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.81% | 66,146 | +6% | 0% | $313,045 |
| UBS Group AG | 0.61% | 50,070 | +3484% | 0% | $236,831 |
| STALEY CAPITAL ADVISERS INC | 0.61% | 50,000 | 0% | 0.01% | $236,500 |
| MILLENNIUM MANAGEMENT LLC | 0.58% | 47,689 | 0% | $225,569 | |
| JANE STREET GROUP, LLC | 0.41% | 33,870 | +142% | 0% | $160,206 |
| VANGUARD FIDUCIARY TRUST CO | 0.41% | 33,621 | 0% | 0% | $159,027 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.4% | 32,691 | 0% | 0% | $154,628 |
| STATE STREET CORP | 0.32% | 26,453 | 0% | 0% | $125,123 |
| FMR LLC | 0.2% | 16,238 | -5.4% | 0% | $76,806 |
| NORTHERN TRUST CORP | 0.15% | 12,340 | 0% | 0% | $58,368 |
| MORGAN STANLEY | 0.11% | 9,169 | -43% | 0% | $43,370 |
| ROYAL BANK OF CANADA | 0.05% | 4,319 | +408% | 0% | $20,000 |
| SBI Securities Co., Ltd. | 0.02% | 1,574 | +12% | 0% | $7,445 |
| Vanguard Global Advisers, LLC | 0.02% | 1,456 | 0% | 0% | $6,887 |
| JONES FINANCIAL COMPANIES LLLP | 0.01% | 703 | 0% | 0% | $3,227 |
| WELLS FARGO & COMPANY/MN | 0% | 251 | 0% | 0% | $1,187 |
| JPMORGAN CHASE & CO | 0% | 216 | 0% | 0% | $933 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,564,231 | $12,126,243 | -$2,698,909 | $4.73 | 33 |
| 2025 Q4 | 2,049,655 | $37,062,796 | +$3,113,209 | $18.09 | 40 |
| 2025 Q3 | 1,883,136 | $26,983,314 | +$1,944,887 | $14.33 | 36 |
| 2025 Q2 | 1,803,350 | $13,921,685 | -$1,938,164 | $7.72 | 32 |
| 2025 Q1 | 2,086,793 | $12,393,904 | -$4,023,428 | $5.94 | 36 |
| 2024 Q4 | 2,368,286 | $31,519,295 | -$410,987 | $13.31 | 41 |
| 2024 Q3 | 2,414,500 | $19,628,975 | -$1,762,796 | $8.13 | 33 |
| 2024 Q2 | 2,653,675 | $22,554,322 | +$22,225,788 | $8.50 | 43 |